Literature DB >> 23262655

[The LUNAR study: rituximab for lupus nephritis?].

C Specker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23262655     DOI： 10.1007/s00393-012-1111-8

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  2 in total

1.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.

Authors:  Joan T Merrill; C Michael Neuwelt; Daniel J Wallace; Joseph C Shanahan; Kevin M Latinis; James C Oates; Tammy O Utset; Caroline Gordon; David A Isenberg; Hsin-Ju Hsieh; David Zhang; Paul G Brunetta
Journal:  Arthritis Rheum       Date:  2010-01

Review 2.  Off-label use of rituximab in systemic lupus erythematosus: a systematic review.

Authors:  Eleanor Murray; Martin Perry
Journal:  Clin Rheumatol       Date:  2010-02-13       Impact factor: 2.980
  2 in total
  1 in total

Review 1.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.